Tennessee is currently home to 1983 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Holston Medical Group_Bristol, Bristol, Tennessee
Conditions: Obesity
Register for Updates
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
NCT06128733
Recruiting
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
06/17/2024
Locations: Pediatric Clinical Trials Tullahoma Site Number : 8400020, Tullahoma, Tennessee
Conditions: Meningococcal Infection, Healthy Volunteers, Meningococcal Immunisation
Register for Updates
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021
Recruiting
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A*11:01. The purpose of this study is to find the best dose of AFNT-211 th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Register for Updates
Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions
NCT06077201
Recruiting
The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage participation in CBCR are important, many individuals will still not participate for a variety of reasons. This randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients undergoing transcatheter heart valve interventions (THVIs). After a brief r... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Valvular Heart Disease
Register for Updates
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562
Recruiting
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: New Phase Research and Development, Knoxville, Tennessee
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748
Recruiting
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: West Cancer Center, Germantown, Tennessee
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Gastro One /ID# 256614, Cordova, Tennessee
Conditions: Crohn's Disease
Register for Updates
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Nashville Skin: Comprehensive Dermatology Center, Nashville, Tennessee
Conditions: Moderate Plaque Psoriasis
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Nashville, Tennessee
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
NCT05954312
Recruiting
A FIH study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-130037 in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Advanced Solid Tumors
Register for Updates
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066
Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Vanderbilt Health One Hundred Oaks, Nashville, Tennessee
Conditions: Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea
Register for Updates
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
Recruiting
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: West Cancer Center & Research Institute, Germantown, Tennessee
Conditions: Urothelial Carcinoma
Register for Updates